We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blood Glucose Monitoring System Designed for Accuracy

By LabMedica International staff writers
Posted on 29 Jul 2013
Recently more attention has been drawn to the accuracy requirements for blood glucose monitoring systems (BGMS) for home use as well as those for hospital use.

Tighter accuracy criteria are being introduced internationally for BGMS and therefore newer systems need to be evaluated for point-of-care testing (POCT) of blood glucose, a valuable biomarker for the management of patients with diabetes and other conditions. More...


Collaborating scientists from three different institutions and the commercial manufacturer evaluated a BGMS in a multicenter study for precision, interference, and system accuracy using 503 blood samples from capillary, venous, and arterial sources. Included in the study was interference testing, both hematocrit and other substances, and accuracy evaluations. The institutes were the Rainier Clinical Research Center (Renton, WA, USA), the Duke University Medical Center (Durham, NC, USA), and MassResearch LLC (Waltham, MA, USA).

The FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System (Abbott Diabetes Care; Alameda, CA, USA) is designed to simplify POCT for healthcare professionals, providing features that enhance the reliability of the testing process and support compliance with POCT policies. The FreeStyle Precision Pro blood glucose-test strip is individually sealed, and each test strip contains three electrodes, working, reference, and fill trigger. The circuit between the fill trigger and the reference electrodes must be detected by the meter before the test will start. The minimum sample volume required is 0.6 μL and the test time is five seconds.

The FreeStyle Precision Pro system demonstrated acceptable precision, no interference across a hematocrit range of 15% to 65%, and, except for xylose, no interference from 24 of 25 potentially interfering substances. From the individual results of various blood sample types, 97.3% to 98.9% agreed within ±12 mg/dL of the laboratory analyzer values at glucose concentrations less than 100 mg/dL and within ±12.5% of the laboratory analyzer values at glucose concentrations equal to or greater than 100 mg/dL.

The authors concluded that the FreeStyle Precision Pro system makes more measurements and uses more signals from the glucose electrochemical reaction to increase accuracy; it also performs more integrity checks to detect potential errors during each glucose test. The study was published on June 5, 2013, in the journal Clinica Chimica Acta.

Related Links:

Rainier Clinical Research Center
Duke University Medical Center
Abbott Diabetes Care



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.